Digital assessment of Parkinson's disease

Quantitative evaluation of drug response test in patients with Parkinson's disease and the influence of rehabilitation intervention on the evaluation of drug response and the exploration of related mechanisms

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025372

Enrollment

Unknown

Registered

2019-08-25

Start date

2019-08-18

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

1:rehabilitation

1:take levodopa

30:Wear wearable devices

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Clinically confirmed primary PD or clinically probable primary PD; 2. The main manifestations are bradykinesia and myotonia; 3. The recent condition is relatively stable, no need to adjust medicine; 4. H-Y stage I-IV; 5. Have a better desire for recovery, can cooperate with the examination and treatment measures; 6. Informed consent and voluntary participation.

Exclusion criteria

Exclusion criteria: 1. Parkinsonism or Parkinson's superimposed syndrome; 2. PD is characterized by tremor; 3. Severe cognitive impairment was not compatible with investigators, significant visual or auditory impairment, and angle-closure glaucoma; 4. Patients who cannot tolerate levodopa; 5. Severe mental illness; 6. Patients with muscular, skeletal or peripheral nerve diseases, severe hypertension, cardiopulmonary diseases, malignant tumors and other intolerable interventions; 7. Poor compliance and inability to cooperate with investigators.

Design outcomes

Primary

Measure	Time frame
Improvement rate of drug response test;	—

Countries

China

Contacts

Public ContactLiu Peipei

Tianjin Huanhu Hospital

liupeipei2008@sina.com+86 13512204476

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026